Bannerbild German Brest Group

October 2018: Long-term survival analysis of GeparSixto trial

05.11.2018

The survival analysis of patients with triple-negative and HER2-positive early breast cancer enrolled in the neoadjuvant GeparSixto (GBG 66) phase II trial have been published in the Annals of Oncology.

We are delighted to inform you that the survival analysis of patients with triple-negative and HER2-positive early breast cancer enrolled in the neoadjuvant GeparSixto (GBG 66) phase II trial have been published in the Annals of Oncology. The report also included assessment of homologous recombination deficiency (HRD) as a potential prognostic and predictive factor in triple-negative breast cancer.

Loibl S, Weber KE, Timms KM, Elkin EP, Hahnen E, Fasching PA, Lederer B, Denkert C, Schneeweiss A, Braun S, Salat CT, Rezai M, Blohmer JU, Zahm DM, Jackisch C, Gerber B, Klare P, Kümmel S, Schem C, Paepke S, Schmutzler R, Rhiem K, Penn S, Reid J, Nekljudova V, Hartman AR, von Minckwitz G, Untch M. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response - final results from GeparSixto. Ann Oncol. 2018 Oct 18 [Epub ahead of print]

In the neoadjuvant GeparSixto study, adding carboplatin to taxane- and anthracycline-based chemotherapy improved pathological complete response (pCR) rates in patients with triple-negative breast cancer (TNBC) (von Minckwitz et al. Lancet Oncol 2014). TNBC is frequently associated with germline mutations of the BRCA1/2 genes which are critical for repairing DNA double-strand breaks. Homologous recombination deficiency (HRD) of DNA repair is a common feature in BRCA-related tumors and can be consider as a possible DNA repair–targeted treatment approach.
In this study, we showed that carboplatin as part of a neoadjuvant anthracycline/taxane-based chemotherapy statistically significantly improves disease-free survival (DFS; HR=0.56, [95%CI 0.34-0.93]; p=0.022), with a strong trend towards a better overall survival (OS; HR=0.60 [95%CI 0.32-1.12; p=0.106) in TNBC, whereas no significant difference was observed for both DFS and OS in HER2-positive tumors. Hence, these findings support the neoadjuvant use of carboplatin in TNBC. Additionally, in patients with TNBC the HRD was predictor of response but did not predict the effect of carboplatin.


News

  • 30.03.2018 Paper of the month: March 2018

    An analysis of 802 women with triple-negative breast cancer (TNBC) from the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC) and GeparSixto (GBG 66) trial that investigated the association between the age at TNBC diagnosis and the presence of pathogenic germline BRCA1/2 mutations has been published in the BMC Cancer.

    Mehr ...
  • 13.03.2018 ESMO 2019

    ESMO 2019

    ESMO Breast Cancer congress ist taking place in May 2019 in Berlin, Germany.

    Mehr ...
  • 28.02.2018 Paper of the month: February 2018

    The first results of the BrighTNess trial designed to evaluate the addition of veliparib (a PARP inhibitor) plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) have been published in the The Lancet Oncology.

    Mehr ...
  • 02.02.2018 Informationsvideo für Patienten

    Prof. Loibl, Leiterin der GBG und Prof. Jackisch, Chefarzt am Sana Klinikum Offenbach sprechen mit einer Patientin über ihre Erfahrungen in einer klinischen Studie.

    Mehr ...

GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd